Horan Securities’s AstraZeneca AZN Stock Holding History

Horan Securities’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-197	Closed	-$28.2K	–	143
2023 Q2	$28.2K	Hold	197	–	–	0.01%	284
2023 Q1	$27.3K	Sell	197 -18	-8%	-$2.42K	0.01%	270
2022 Q4	$29.1K	Buy	215 +18	+9%	+$2.26K	0.02%	261
2022 Q3	$22K	Hold	197	–	–	0.01%	261
2022 Q2	$26K	Sell	197 -25	-11%	-$3.28K	0.02%	235
2022 Q1	$29K	Hold	222	–	–	0.02%	224
2021 Q4	$26K	Buy	+222	New	+$26.1K	0.02%	222
2021 Q2	$21K	Sell	175 -67	-28%	-$7.35K	0.01%	230
2021 Q1	$24K	Hold	242	–	–	0.02%	200
2020 Q4	$24K	Buy	242 +135	+126%	+$14.3K	0.02%	175
2020 Q3	$12K	Hold	107	–	–	0.01%	198
2020 Q2	$11K	Hold	107	–	–	0.01%	162
2020 Q1	$10K	Buy	+107	New	+$10.1K	0.01%	129
2019 Q4	–	Sell	-107	Closed	-$10K	–	46
2019 Q3	$10K	Hold	107	–	–	0.01%	154
2019 Q2	$9K	Hold	107	–	–	0.01%	178
2019 Q1	$9K	Hold	107	–	–	0.01%	148
2018 Q4	$8K	Hold	107	–	–	0.01%	147
2018 Q3	$8K	Hold	107	–	–	0.01%	128
2018 Q2	$8K	Buy	+107	New	+$7.7K	0.01%	132

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Horan Securities's AZN Position: Q3 2023 in Review

Horan Securities sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 197 shares — an estimated $28.2K sold.

Horan Securities first reported a position in AZN in Q2 2018 and held it in 19 quarters. The position peaked at $29.1K in Q4 2022. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Horan Securities reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Horan Securities sold 197 AstraZeneca shares in Q3 2023, an estimated $28.2K.
Horan Securities first reported a position in AstraZeneca in Q2 2018 and held it in 19 quarters.
Horan Securities's AstraZeneca position peaked at $29.1K in Q4 2022.
1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Horan Securities's 13F filing for Q3 2023, filed 1 Nov 2023.